Breast cancer with concurrent TP53 mutation and MYC amplification demonstrated higher grade and stage, more positive HER2 status, higher Ki67 levels, and more mutations in genes involved in ERBB and TGF‐β signaling pathways, as well as exclusive FANCG/CDKN2B/QKI copy number amplifications. The gene discussed is MYC; the disease is breast cancer.